Indexado en
Licencia y uso
Grant support
This trial was funded by the Fondo de Investigaciones Sanitarias (FIS) del Instituto de Salud Carlos III (ISCIII), the European Regional Development Fund (ERDF) under registration number 07528, as well as the 2016 and 2017 calls for grants for translations and publishing by the Fundacion para la Investigacion e Innovacion Biosanitaria en Atencion Primaria (FIIBAP).
Análisis de autorías institucional
Camarelles Guillem, FranciscoAutor o CoautorSubsidized pharmacological treatment for smoking cessation by the Spanish public health system: A randomized, pragmatic, clinical trial by clusters
Publicado en:Tobacco Induced Diseases. 17 (September): 64-64 - 2019-09-01 17(September), DOI: 10.18332/tid/111368
Autores: Minue-Lorenzo, Cesar; Olano-Espinosa, Eduardo; Del Cura-Gonzalez, Isabel; Vizcaino-Sanchez, Jose M; Camarelles-Guillem, Francisco; Granados-Garrido, Jose A; Ruiz-Pacheco, Margarita; Isabel Gamez-Cabero, M; Javier Martinez-Suberviola, F; Serrano-Serrano, Encarnacion
Afiliaciones
Resumen
Research has shown that financing drug therapy increases smoking abstinence rates, although most of these studies have been carried out in the private healthcare setting. The aim of this work is to assess the effect of subsidized pharmacological treatment on smoking cessation rates by the Spanish public healthcare system.A pragmatic, randomized, clinical trial was performed by clusters. Randomization unit was the primary healthcare center and the analysis unit was the patient. Smokers consuming ≥10 cigarettes/day were randomly assigned to an intervention group that received financed pharmacological treatment or to a control group that followed usual care. The main outcome was self-reported or CO-confirmed continuous abstinence at 12 months. The main outcome, continuous abstinence rates (%), were compared between groups at 12 months post-intervention. A model was adjusted using mixed-effect logistic regression.A total of 1154 patients were included from 23 healthcare centers. In the intention-to-treat analysis, self-reported abstinence after 12 months in the control and intervention groups, respectively, was 9.6% (37/387) and 15.4% (118/767) (gender-adjusted OR=1.75; 95% CI: 1.1-2.8); for CO-confirmed abstinence the corresponding values were 3.1% (12/387) and 6.4% (49/767) (gender-adjusted OR=1.72; 95% CI: 0.7-4.0). Pharmacological treatment use was 35.1% (136/387) in the control group, and 58.3% (447/767) in the intervention group (adjusted OR=4.25; 95% CI: 1.8-9.9).Subsidizing pharmacological treatment for smoking cessation increases self-reported or CO-confirmed abstinence rates under realistic conditions in the primary care setting of the Spanish public health system.© 2019 Minué-Lorenzo C.
Palabras clave
Indicios de calidad
Impacto bibliométrico. Análisis de la aportación y canal de difusión
El trabajo ha sido publicado en la revista Tobacco Induced Diseases debido a la progresión y el buen impacto que ha alcanzado en los últimos años, según la agencia Scopus (SJR), se ha convertido en una referencia en su campo. En el año de publicación del trabajo, 2019, se encontraba en la posición , consiguiendo con ello situarse como revista Q2 (Segundo Cuartil), en la categoría Health (Social Science). Destacable, igualmente, el hecho de que la Revista está posicionada en el Cuartil Q3 para la agencia WoS (JCR) en la categoría Public, Environmental & Occupational Health.
Desde una perspectiva relativa, y atendiendo al indicador del impacto normalizado calculado a partir del Field Citation Ratio (FCR) de la fuente Dimensions, arroja un valor de: 3.47, lo que indica que, de manera comparada con trabajos en la misma disciplina y en el mismo año de publicación, lo ubica como trabajo citado por encima de la media. (fuente consultada: Dimensions May 2025)
De manera concreta y atendiendo a las diferentes agencias de indexación, el trabajo ha acumulado, hasta la fecha 2025-05-29, el siguiente número de citas:
- WoS: 10
- Scopus: 12
- Europe PMC: 6
- OpenCitations: 10